GlaxoSmithKline plc (GSK) Shares Bought by Neuberger Berman Group LLC

Neuberger Berman Group LLC boosted its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 1.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 991,683 shares of the pharmaceutical company’s stock after buying an additional 15,660 shares during the quarter. Neuberger Berman Group LLC’s holdings in GlaxoSmithKline were worth $40,262,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its stake in GlaxoSmithKline by 1.9% during the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock worth $137,000 after buying an additional 64 shares during the period. FTB Advisors Inc. raised its holdings in GlaxoSmithKline by 16.9% in the second quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock valued at $146,000 after acquiring an additional 539 shares in the last quarter. Advisory Services Network LLC raised its holdings in GlaxoSmithKline by 24.2% in the second quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock valued at $175,000 after acquiring an additional 788 shares in the last quarter. Parallel Advisors LLC raised its holdings in GlaxoSmithKline by 93.4% in the second quarter. Parallel Advisors LLC now owns 4,048 shares of the pharmaceutical company’s stock valued at $164,000 after acquiring an additional 1,955 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its holdings in GlaxoSmithKline by 3.5% in the second quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock valued at $162,000 after acquiring an additional 148 shares in the last quarter. Institutional investors and hedge funds own 9.82% of the company’s stock.

In related news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The shares were acquired at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.00% of the company’s stock.

GSK has been the topic of a number of analyst reports. TheStreet raised GlaxoSmithKline from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Wednesday, October 18th. Argus lowered their price target on GlaxoSmithKline to $40.00 and set a “buy” rating for the company in a report on Thursday, November 30th. UBS Group upgraded GlaxoSmithKline from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $35.04 to $35.85 in a report on Monday, November 27th. Finally, Investec lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $38.57.

Shares of GlaxoSmithKline plc (NYSE GSK) traded up $0.44 during midday trading on Thursday, hitting $36.84. The stock had a trading volume of 4,567,386 shares, compared to its average volume of 6,198,697. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. GlaxoSmithKline plc has a fifty-two week low of $34.52 and a fifty-two week high of $44.53. The firm has a market cap of $90,420.00, a price-to-earnings ratio of 28.78, a price-to-earnings-growth ratio of 2.15 and a beta of 0.97.

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be given a dividend of $0.5037 per share. This represents a $2.01 annualized dividend and a dividend yield of 5.47%. The ex-dividend date of this dividend is Thursday, November 9th. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio (DPR) is 159.38%.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2018/01/11/neuberger-berman-group-llc-boosts-holdings-in-glaxosmithkline-plc-gsk.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply